Regentatlantic Capital LLC boosted its position in shares of Becton Dickinson and Co (NYSE:BDX) by 22.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,655 shares of the medical instruments supplier’s stock after buying an additional 1,233 shares during the quarter. Regentatlantic Capital LLC’s holdings in Becton Dickinson and were worth $1,677,000 at the end of the most recent reporting period.
Other hedge funds have also recently added to or reduced their stakes in the company. Duality Advisers LP grew its position in Becton Dickinson and by 12.7% during the first quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock valued at $4,365,000 after buying an additional 1,970 shares during the period. Meridian Wealth Advisors LLC grew its position in Becton Dickinson and by 2.7% during the first quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock valued at $946,000 after buying an additional 99 shares during the period. Pratt Collard Advisory Partners LLC grew its position in Becton Dickinson and by 5.1% during the first quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock valued at $519,000 after buying an additional 100 shares during the period. Investec Asset Management North America Inc. grew its position in Becton Dickinson and by 5.1% during the first quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock valued at $2,778,000 after buying an additional 543 shares during the period. Finally, Black Diamond Financial LLC acquired a new stake in Becton Dickinson and during the second quarter valued at $562,000. Institutional investors own 84.80% of the company’s stock.
Shares of NYSE BDX traded down $3.66 during trading on Friday, hitting $248.69. The company had a trading volume of 1,166,959 shares, compared to its average volume of 766,165. The firm’s fifty day simple moving average is $250.17. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $265.87. The firm has a market capitalization of $68.19 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 1.87 and a beta of 1.11. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.02. The firm had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company’s revenue for the quarter was down .6% on a year-over-year basis. During the same period last year, the firm posted $2.65 earnings per share. Sell-side analysts predict that Becton Dickinson and Co will post 11.68 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.24%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.
Several analysts recently commented on the stock. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. UBS Group dropped their target price on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. KeyCorp reiterated an “overweight” rating and issued a $262.00 target price (down previously from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Barclays upgraded shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 target price on the stock in a research report on Monday, May 13th. Finally, BMO Capital Markets dropped their target price on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Six analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $263.58.
In other news, EVP Simon D. Campion sold 2,903 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total value of $687,836.82. Following the transaction, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at $2,229,131.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick Kaltenbach sold 191 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $241.03, for a total transaction of $46,036.73. Following the completion of the transaction, the executive vice president now directly owns 19,072 shares in the company, valued at $4,596,924.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,154 shares of company stock worth $4,955,775. Insiders own 0.12% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Total Return
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.